Lundbeck Fails To Escape NeoProfen Antitrust Suits

Law360, New York (July 21, 2009, 7:46 PM EDT) -- Lundbeck Inc. on Tuesday lost its bid to toss a pair of suits launched by the Federal Trade Commission and the state of Minnesota accusing the drugmaker of jacking up the price of a NeoProfen, a drug used to treat a heart condition in premature infants, after cornering the market in 2006.

Judge Joan N. Ericksen of the U.S. District Court for the District of Minnesota denied motions for summary judgment filed by Lundbeck, formerly known as Ovation Pharmaceuticals Inc., finding that significant legal issues persisted....
To view the full article, register now.